RGBP · Regen BioPharma Inc
$0.00
+0.00 (+0.00%)
At close · Sep 1
Going-concern doubt
— flagged Aug 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.”View the 10-Q filed Aug 17, 2026
Market Cap
$167,527
Shares
1.68B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.03
Avg vol 30d16.3M
Short int10K · 0.0% float · 1.0d
Short vol100%
DataNov 2024–Sep 2026
Filing10-Q · Aug 17
Raw chart and full-history price indicators begin at the captured split on Nov 4, 2024; bars on opposite sides are not compared.
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 17, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−96%
below
Price vs 50-day avg
0%
above
RSI (14)
46
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−50%
trailing
6-month return
−88%
trailing
YTD return
−99%
this year
Relative strength
−100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
+69%
Y/Y
Quant / Vol
risk profile
Volatility
451%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
100.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−96%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
46
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -96%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGBP
this stock
Regen BioPharma Inc
|
$167,527 | -98.6% | +0.8% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +6.7% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- THOMPSON INVESTMENT MANAG…
Held
Float
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Nov 4, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGBP | +0.0% | -50.0% | -87.5% | +0.0% | -98.7% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | +0.5% | -48.8% | -100.1% | +0.7% | -110.4% |